Home / Press Release (page 3)

Category Archives: Press Release

Feed Subscription

Shell Invests in LanzaJet to Further Accelerate the Global Commercialization of LanzaJet’s Leading Alcohol-to-Jet Technology to Address the Aviation Sector’s Urgent Need to Decarbonise

CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) — Our world is at an inflection point – one that requires action today, solutions that work, and meaningful progress toward decarbonizing industries and our society. LanzaJet, Inc., a leading sustainable fuels technology company and sustainable fuels producer, announced today that Shell joins as an investor in the company […]

Read More »

JETEX LAUNCHES THE WORLD’S MOST EXCLUSIVE IFTAR EXPERIENCE

Iftar in the Skies offers breathtaking aerial views of iconic landmarks and natural vistas across the UAE. Luxury private jet journey starts in Dubai just before sunset during the Holy Month of Ramadan. Dubai, United Arab Emirates, April 05, 2021 (GLOBE NEWSWIRE) — Dubai-based Jetex, a global leader in executive aviation, is inviting residents and […]

Read More »

JETEX LAUNCHES THE WORLD’S MOST EXCLUSIVE IFTAR EXPERIENCE

Iftar in the Skies offers breathtaking aerial views of iconic landmarks and natural vistas across the UAE. Luxury private jet journey starts in Dubai just before sunset during the Holy Month of Ramadan. Dubai, United Arab Emirates, April 05, 2021 (GLOBE NEWSWIRE) — Dubai-based Jetex, a global leader in executive aviation, is inviting residents and […]

Read More »

‫یو ایس ایف ڈی اے نے جیمن کیئر کو نیوٹرلائزنگ اینٹی باڈی JMB2002 کے کلینیکل ٹرائل کے آغاز کی منظوری دے دی ہے

شنگھائی، 2 اپریل 2021/ ژن ہوا- ایشیا نیٹ/– 31 مارچ 2021 کو جیمن کیئر گروپ نے اعلان کیا کہ ان کے اینٹی- سارس- کوو-2 اینٹی باڈی JMB2002کو جسےجیمن کیئر شنگھائی ریسرچ سینٹر نے آزادانہ طور پر تیار کیاتھا، ایف ڈی اے نے امریکہ میں کلینیکل ٹرائل کے لئے منظوری دے دی ہے۔ پری کلینیکل اعداد […]

Read More »

US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002

SHANGHAI, Apr. 2, 2021 /Xinhua-AsiaNet/–On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial in the United States. Preclinical data showed that JMB2002 can precisely occupy the key epitope of the receptor binding domain (RBD) on the S1 […]

Read More »
Scroll To Top